The prognosis for melanoma is often favorable, especially when the condition is diagnosed early. More than 95 percent of people with stage 1A melanoma live for 10 or more years following diagnosis, as do more than 86 percent of people with stage 1B melanoma. This is why early detection is so important, and also why Moffitt Cancer Center in Tampa, Florida, offers a comprehensive range of treatments for melanoma and other forms of skin cancer.
A patient’s melanoma prognosis is influenced by the stage of the cancer at the time of diagnosis, as well as:
- The type of treatment that he or she receives – Patients who have access to leading-edge therapies, such as immunotherapies and advanced forms of surgery, often have the most favorable outcomes.
- The expertise of his or her treatment team – Every patient has highly unique needs that must be considered during treatment. Oncologists who have the experience necessary to fully consider these needs can help their patients achieve the best possible outcomes.
- The unique way that his or her body responds to treatment – It’s impossible to predict how an individual will respond to chemotherapy, radiation therapy or any other kind of melanoma treatment. Sometimes, oncologists need to create follow-up plans with secondary treatments, which may include clinical trials.
At Moffitt, we’re committed to improving survival rates and helping each patient improve his or her melanoma prognosis by implementing the latest advances in early detection, providing individualized treatment plans and facilitating access to promising new therapies through our clinical trials.
Referrals are welcome, but never required at Moffitt. To discuss the best ways to improve your melanoma prognosis with one of our experienced oncologists, call 1-888-663-3488 or submit a new patient registration form online.